DBV Technologies reported $39.82M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amarin USD 36.71M 8M Sep/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
DBV Technologies USD 39.82M 972K Sep/2025
Esperion Therapeutics USD 77.51M 2.81M Sep/2025
Galectin Therapeutics USD 3.7M 99K Jun/2024
Halozyme Therapeutics USD 20.9M 5.54M Dec/2025
Incyte USD 1.63B 1.46B Dec/2025
Insmed USD 79.91M 316K Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
United Therapeutics USD 468M 36M Sep/2025